article thumbnail

Exercise hormone may modulate genes associated with replication of novel coronavirus

Scienmag

Brazilian researchers observed that in uninfected adipocytes, the hormone irisin altered the expression of genes that regulate ACE-2, which encodes a protein to which the virus binds in order to invade human cells.

article thumbnail

Amvuttra RNAi Therapeutic Wins FDA Approval for Rare Genetic Protein Disorder

XTalks

Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Genetic biomarkers could personalise therapy for TNBC

Drug Discovery World

A new study has shed light on the genetic messages encoded by genes within ‘triple negative’ breast cancers (TNBC), and shows they could predict response to chemotherapy. The presence of these biomarkers could be used to accelerate the development of more personalised treatments for triple negative breast cancers.

article thumbnail

Genetically modified mice pave the way for customized medicine in a rare disease

Medical Xpress

Ana Guadaño at the Alberto Sols Biomedical Research Institute (IIBM, a combined CSIC-UAM center) and involving the Complutense University of Madrid (UCM), used CRISPR gene editing techniques to incorporate into mice a mutation of the MCT8 protein responsible for transporting thyroid hormones to the interior of the cell.

article thumbnail

Merck & Co signs multi-billion cancer drug development deal with Seattle Genetics

pharmaphorum

Merck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion in partner Seattle Genetics. The drug zeroes in on cancer cells expressing a protein known as LIV-1 and is in phase 1 development for breast cancer and other solid tumours. billion equity investment in 5.0

article thumbnail

Targeted breast cancer drug extends lives of patients in Phase III trial

Drug Discovery World

The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most common type of breast cancer. . Capivasertib is a potential first-in-class drug that blocks activity of the cancer-driving protein molecule AKT. Genetic alterations of the AKT pathway.

Trials 52
article thumbnail

HPAPIs – Current Interest of the Pharmaceutical Industry

Roots Analysis

This has led to their widespread production and extensive use in the treatment of various indications including hormonal imbalances, oncological disorders and respiratory disorders. The ADCs bind to specific proteins or peptides in cancer cells with very high specificity and efficacy influencing the biological functions.